Chemical subgroup
L04AJ – Komplement-Inhibitoren
17Decisions
21Patient groups
Added benefit by patient group
- Minor2
- Non-quantifiable5
- Not proven14
Decisions, newest first
- 2026-08-06AspaveliPegcetacoplanNon-quantifiable
- 2026-08-06AspaveliPegcetacoplanNon-quantifiable
- 2026-06-04FabhaltaIptacopanNot proven
- 2026-06-04FabhaltaIptacopanNot proven: 2 of 2 patient groups
- 2026-03-05TavneosAvacopanNot proven
- 2025-03-06PiaSkyCrovalimabNot proven: 2 of 2 patient groups
- 2024-11-22VoydeyaDanicopanNon-quantifiable
- 2024-11-22AspaveliPegcetacoplanNon-quantifiable
- 2024-08-15ZilbrysqZilucoplanNot proven
- 2023-12-07UltomirisRavulizumabNot proven
- 2023-06-15EnjaymoSutimlimabMinor
- 2023-04-20UltomirisRavulizumabNot proven
- 2022-09-15AspaveliPegcetacoplanNon-quantifiable
- 2022-08-04TavneosAvacopanMinor
- 2022-03-18UltomirisRavulizumabNot proven: 2 of 2 patient groups
- 2021-01-21UltomirisRavulizumabNot proven
- 2020-02-06UltomirisRavulizumabNot proven: 2 of 2 patient groups
Data status: 2026-10-29